FDA’s Breakthrough Designations Face Question Of Review Resources
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Woodcock says FDA will manage breakthrough applications along with its entire portfolio of submissions, but some stakeholders express concern about whether the demands of the exceedingly popular program will affect the agency’s handling of other applications.
You may also be interested in...
Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?
Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.
Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?
Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
Members will enter data into secure database, allowing trade groups to gauge trends and problems with the PDUFA V application review program – and giving industry a stronger negotiating position for the next user fee round.